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Introduction: The phosphatidylinositol 3-kinase (PI3K) pathway pro-
motes tumor growth and treatment resistance in non-small cell lung 
cancer (NSCLC). The aim of the open-label, two-stage, Phase II study 
BASALT-1 (NCT01820325) was to investigate the pan-PI3K inhibi-
tor buparlisib (BKM120) in patients with PI3K pathway-activated, 
relapsed NSCLC.
Methods: After prescreening for PI3K pathway activation, patients 
with PI3K pathway-activated, metastatic, squamous or nonsquamous 
NSCLC, who had relapsed after prior systemic antineoplastic ther-
apy, were enrolled. In Stage 1, patients received single-agent bupar-
lisib (100 mg/day). A futility analysis was performed independently 
in each histology group, based on the 12-week progression-free sur-
vival rate for the first 30 patients treated in each group being less than 
50%. Exploratory biomarker analyses were performed in archival tis-
sue samples and circulating tumor DNA (ctDNA).
Results: Of 1242 prescreened patients, 13.5% exhibited PI3K 
pathway activation. As of June 5, 2014, 63 patients (30 squamous 
and 33 nonsquamous) were treated in Stage 1. The 12-week pro-
gression-free survival rates were 23.3% (95% confidence interval: 
9.9–42.3) and 20.0% (95% confidence interval: 7.7–38.6) in the 
squamous and nonsquamous groups, respectively. Stage 2 was 
therefore not initiated in either group. PI3K pathway mutations 
in ctDNA were more concordant with metastatic tissue than with 
primary biopsies.
Conclusions: Despite preselecting patients for targeted treatment, 
BASALT-1 did not meet its primary objective during Stage 1. PI3K 
pathway activation can be detected using ctDNA, but may not be the 
main oncogenic driver in NSCLC. Combinations of PI3K inhibitors 
with other agents may demonstrate greater efficacy than monotherapy.
Key Words: Buparlisib/BKM120, PI3K pathway activation, 
Squamous NSCLC, Nonsquamous NSCLC.
(J Thorac Oncol. 2015;10: 1319–1327)
Lung cancer is the leading cause of cancer-related death in the European Union, responsible for an estimated 270,000 
deaths in 2014.1 Non-small cell lung cancer (NSCLC) 
accounts for 80%–85% of all lung cancer cases, and can be 
classified by histology into squamous carcinoma (20% of all 
lung cancer) and nonsquamous carcinoma (including adeno-
carcinoma; 40% of all lung cancer).2,3
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The paradigm for treatment of advanced NSCLC has 
evolved from an approach based on a patient’s ability to withstand 
the toxicities of chemotherapy to one that incorporates disease 
histology and molecular genotype as predictive markers of ben-
efit from targeted agents.4 In patients with advanced, recurrent 
NSCLC, single-agent docetaxel, or pemetrexed (for nonsqua-
mous NSCLC), are established second-line agents.4 However, 
the clinical outcome in this setting is poor, with a response rate 
of less than 10%, and progression-free survival (PFS) and over-
all survival (OS) in the range of 2.7–3.0 months and 7.4–8.0 
months, respectively.5–7 In patients without oncogenic drivers 
(e.g., EGFR activating mutations or ALK translocation), the out-
come with targeted agents, such as erlotinib is similarly poor, if 
not inferior.8 For both squamous and nonsquamous metastatic, 
recurrent NSCLC, treatment options are limited.
The phosphatidylinositol 3-kinase (PI3K)/AKT/mam-
malian target of rapamycin pathway is frequently dysregu-
lated in cancer and is implicated in oncogenesis and tumor 
progression, as well as resistance to standard anticancer 
therapies.9 Previous studies have reported activating muta-
tions in PIK3CA (encoding the catalytic subunit PI3Kα)10–12 
and alterations (mutation or loss of expression) of the tumor 
suppressor phosphatase and tensin homolog (PTEN)13–16 in a 
clinically meaningful proportion of patients with squamous 
and nonsquamous NSCLC.
Preclinical studies suggest that targeting the PI3K path-
way could be an effective treatment strategy in patients with 
NSCLC—simultaneous inhibition of multiple PI3K pathway 
components blocks the growth of PI3K-dependent NSCLC 
cell lines, and induces tumor regression in mouse xenograft 
models of PIK3CA-mutant lung cancer.17–19
Buparlisib (BKM120) is an oral PI3K inhibitor that 
selectively targets all four isoforms of Class I PI3K (α, β, γ, 
and δ).20 Single-agent buparlisib has demonstrated antipro-
liferative, proapoptotic, and antitumor activity in a variety of 
cell lines and xenograft models from cancers with and without 
aberrant PI3K pathway activation.20–24 In preclinical studies, 
approximately half of NSCLC cell lines (three of seven squa-
mous and 15 of 28 nonsquamous) were sensitive to buparl-
isib (data on file), suggesting that buparlisib treatment may be 
beneficial in patients with NSCLC.
The aim of BASALT-1, an open-label, two-stage, 
Phase II study (NCT01820325≥), was to assess the safety 
and efficacy of buparlisib in patients with relapsed NSCLC 
harboring documented aberrations in the PI3K pathway. 
Here, we present biomarker data detailing the frequency of 
PIK3CA and PTEN alterations in 1242 patients prescreened 
for the BASALT-1 study, as well as further characterization of 
the molecular underpinnings of PI3K pathway activation in 
NSCLC using circulating tumor DNA (ctDNA) for PIK3CA 
mutation analysis. We also present safety and efficacy results 
from the first 63 patients enrolled and treated in Stage 1.
MATERIALS AND METHODS
PI3K Pathway Analysis
Before screening and enrollment for BASALT-1, PI3K 
pathway activation status was measured in archival or fresh 
biopsy tissue in patients with previously treated, metastatic 
squamous and nonsquamous NSCLC. Pathway activation was 
defined as PIK3CA mutation, PTEN mutation, or PTEN negative 
(less than 10% protein expression by immunohistochemistry).
PIK3CA mutations (exons 1, 5, 7, 9, and 20) and PTEN 
mutations (exons 1–9) were identified by Sanger sequencing 
at central facilities; local PIK3CA mutation analysis was per-
mitted at validated sites, and was most commonly performed 
by SNaPshot assay.25 PTEN expression was assessed cen-
trally by immunohistochemistry using a PTEN antibody (Cell 
Signaling Technology, Inc., Danvers, MA).
Patient Eligibility
Adult patients (≥18 years of age) with metastatic NSCLC 
previously treated with one prior platinum-based chemotherapy 
line (squamous histology), or one or two prior systemic anti-
neoplastic therapy lines (nonsquamous histology), were eligi-
ble for the study. Only patients with confirmed PI3K pathway 
activation at prescreening, as defined above, were considered. 
Patients with a known EGFR activating mutation must have 
been previously treated with at least one EGFR tyrosine kinase 
inhibitor. Other key inclusion criteria included having Eastern 
Cooperative Oncology Group (ECOG) performance status less 
than or equal to two, measurable and/or nonmeasureable disease 
per Response Evaluation Criteria In Solid Tumors (RECIST) 
v1.1, and laboratory values within normal ranges.
Patients previously treated with a PI3K inhibitor or cur-
rently receiving an approved or investigational antineoplastic 
drug were excluded from the trial, as were patients with a history 
of cardiac ≥dysfunction or those taking medication with a known 
risk of prolonging QT interval or inducing Torsades de Pointes. 
As hyperglycemia is a class effect of PI3K inhibitors, patients 
with poorly controlled diabetes mellitus (HbA
1c
 greater than 8%) 
were excluded. Patients with any of the following mood disorders 
were also excluded: history of major depressive episode, bipolar 
disorder, obsessive–compulsive disorder, schizophrenia, suicidal 
attempt or ideation, homicidal ideation, or anxiety Grade ≥3 per 
Common Terminology Criteria for Adverse Events (CTCAE) 
v4.03. Mood disorders were assessed by the investigator or a psy-
chiatrist, and by patient-rated questionnaires (a score of ≥12 on 
the 9-item patient health questionnaire [PHQ-9] or ≥15 on the 
7-item generalized anxiety disorder scale [GAD-7]).
Ethics
The protocol, informed consent form, and any pro-
tocol amendments were approved by an Independent Ethics 
Committee. All participating patients provided written 
informed consent and agreed to comply with the protocol. 
The study was conducted in accordance with the International 
Conference on Harmonization’s Harmonized Tripartite 
Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/≥20/≥EC and 
US Code of Federal Regulations Title 21), and with the ethical 
principles laid down in the Declaration of Helsinki.
Study Design and Treatment
Eligible patients were enrolled in two groups defined by 
squamous and nonsquamous tumor histology. In Stage 1, the 
first 30 patients in each group with confirmed PI3K pathway 
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activation status and meeting the eligibility criteria received 
single-agent oral buparlisib at the maximum tolerated dose 
of 100 mg/day26 on a continuous schedule in 21-day treat-
ment cycles (Supplementary Figure 1, Supplemental Digital 
Content, http://links.lww.com/JTO/A850). Dosing continued 
until disease progression, intolerable toxicity, death, start of 
a new antineoplastic medication, or until the patient discon-
tinued for any reason. In Stage 2, approximately 60 patients 
in each group would be randomized in a 2:1 ratio to receive 
either buparlisib (100 mg/day) or chemotherapy (3-weekly 
docetaxel 75 mg/m2 or pemetrexed 500 mg/m2).
A futility analysis was performed in Stage 1 indepen-
dently for each group, after 30 patients had been enrolled and 
observed for 12 weeks from the first day of treatment. The futil-
ity criterion was defined as a 12-week PFS rate (based on local 
investigator assessment per RECIST v1.1) less than 50% in the 
intent-to-treat population, and was based on the median PFS of 
approved agents in this setting.5–7 Thirty patients were enrolled 
in each group to estimate the 12-week PFS rate with adequate 
precision. If the futility criterion was met, enrollment would be 
stopped and Stage 2 would not be initiated for that group.
Study Objectives
In Stage 1, the primary objective was to assess prelimi-
nary activity of buparlisib independently for each histology 
group, based on the 12-week PFS rate. In Stage 2, the primary 
objective was to evaluate the efficacy of buparlisib compared 
with chemotherapy in each histology group, based on PFS per 
RECIST v1.1.
Secondary objectives were to evaluate OS, overall 
response rate (ORR), disease control rate, time to response, 
and duration of response; and to characterize safety, based 
on the frequency and severity of adverse events (AEs) per 
CTCAE v4.03.
Key exploratory objectives were to evaluate individual 
components of the PI3K pathway in patients with squamous 
and nonsquamous NSCLC, to assess the impact of PIK3CA 
mutations or PTEN alterations on PFS, and to identify other 
biomarkers predictive of response to buparlisib.
Safety and Efficacy Assessments
Radiological assessments (per RECIST v1.1) were per-
formed at 6-week intervals (±7 days) until disease progression. 
Laboratory evaluations were performed throughout the study, 
and included hematology, biochemistry, glucose monitoring, 
coagulation, lipase, and urinalysis. Safety was monitored 
by physical examination, vital signs, weight, ECOG perfor-
mance status, electrocardiogram, cardiac imaging, and assess-
ment of patient-rated questionnaires (PHQ-9 and GAD-7). 
Serious and nonserious AEs were monitored throughout the 
study, described per the Medical Dictionary for Regulatory 
Activities (MedDRA) v17.0, and graded per CTCAE v4.03.
Additional Biomarker Assessments
In addition to PIK3CA and PTEN assessment of tumor 
tissue at prescreening, mutation analysis of ctDNA was per-
formed using BEAMing technology (Sysmex Inostics, Inc., 
Mundelein, IL). A wider set of genetic alterations was assessed 
in archival tissue samples by next-generation sequencing 
(NGS; Illumina HiSeq, Illumina, Inc., San Diego, CA).
RESULTS
PI3K Pathway Analysis
Assessment of PIK3CA and PTEN alterations in 1242 
patients with NSCLC at the prescreening stage (668 squamous 
and 574 nonsquamous) showed that 13.5% of patients exhibited 
PI3K pathway activation (Supplementary Table 1, Supplemental 
Digital Content, http://links.lww.com/JTO/A850).
Patient Characteristics
As of June 5, 2014, 63 patients were recruited onto Stage 
1 of this Phase II study—30 patients in the squamous group 
and 33 patients in the nonsquamous group (Supplementary 
Figure 1, Supplemental Digital Content, http://links.lww.com/
JTO/A850). All patients received at least one dose of buparlisib 
(100 mg/day) and had a post-baseline safety assessment, hence 
were evaluable for safety and efficacy (Table 1). Chemotherapy 
was the most common last prior therapy in 53.3% and 54.5% of 
patients in the squamous and nonsquamous groups, respectively. 
In the squamous group, radiotherapy was the second-most com-
mon (33.3% of patients), whereas in the nonsquamous group, 
patients had received radiotherapy (15.2%), targeted therapy, or 
surgery (12.1% each) as last therapy. Best response at last ther-
apy was partial response (PR) in 43.3% of squamous patients 
and stable disease in 48.5% of nonsquamous patients.
All patients enrolled (N = 63) had tumors with confirmed 
PI3K pathway activation (Table 2). PIK3CA mutations (regard-
less of PTEN alterations) were more common in the nonsqua-
mous than the squamous group (45.2% vs. 20.7% of tumors 
assessed). The most common mechanism of PI3K pathway acti-
vation in both histotypes was PTEN alteration in the absence of 
PIK3CA mutations, occurring in 63.3% of squamous tumors 
and 36.4% of nonsquamous tumors. Concomitant PIK3CA 
mutation and PTEN alteration was infrequent, occurring in 
only 3.3% of the squamous group and 9.1% of the nonsqua-
mous group. Among patients with known PTEN mutation and 
expression status, simultaneous PTEN mutation and PTEN loss 
occurred in 8.0% of patients (2 of 25) in the squamous group 
and 5.6% of patients (1 of 18) in the nonsquamous group.
KRAS mutations were analyzed by Sanger sequencing at 
baseline in all patients for whom sufficient biopsy tissue was 
available. KRAS mutations were observed in 12.0% of tumor 
samples (3 of 25) in the nonsquamous group, and in none of 
the tumor samples (0 of 14) in the squamous group.
NGS analysis was performed in 23 (11 squamous and 
12 nonsquamous) of the 63 enrolled patients, producing a 
genetic profile broadly in line with existing data published 
by The Cancer Genome Atlas (TCGA). The most commonly 
altered genes were TP53, followed by PIK3CA and EGFR.
Patient Disposition
As of June 5, 2014, all 30 patients enrolled in the squa-
mous group, and 32 patients in the nonsquamous group, had 
discontinued study treatment. In the squamous group, AEs 
and progressive disease were the most common reasons for 
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treatment discontinuation (36.7% of patients each), and two 
patients (6.7%) discontinued due to death (one due to sepsis 
and one due to rapidly progressive NSCLC). In the nonsqua-
mous group, progressive disease was the most common reason 
for treatment discontinuation (57.6% of patients) followed by 
AEs (18.2%), and one patient (3.0%) discontinued due to death 
(due to disease progression). One patient in the nonsquamous 
group continued to receive treatment at the cut-off date.
Clinical Activity
The PFS rate in Stage 1 was calculated after 30 patients 
in each group had received treatment for 12 weeks. The 
observed 12-week PFS rates were 23.3% (95% confidence 
interval [CI]: 9.9–42.3) in the squamous group (n = 30) 
and 20.0% (95% CI: 7.7–38.6) in the nonsquamous group 
(n = 30). The futility criterion (12-week PFS less than 50%) 
was met in both histology groups, and Stage 2 was therefore 
not initiated.
Two patients achieved a PR in each of the squamous 
and nonsquamous histology groups. The ORR (complete 
response + PR) was 3.3% (95% CI: 0.1–17.2) in the squa-
mous group and 3.0% (95% CI: 0.1–15.8) in the nonsqua-
mous group (Table 3). Disease control rate was 46.7% 
(95% CI: 28.3–65.7) in the squamous group and 45.5% 
(95% CI: 28.1–63.6) in the nonsquamous group. Waterfall 
plots are shown in Figure 1. The first patient with a PR 
TABLE 1.  Patient Characteristics at Baseline
Characteristic
Squamous
n = 30
Nonsquamous
n = 33
Total
N = 63
Median age, years (range) 65.5 (46.0–78.0) 63.0 (39.0–77.0) 65.0 (39.0–78.0)
Male patients, n (%) 21 (70.0) 19 (57.6) 40 (63.5)
Race, n (%)
  Caucasian 20 (66.7) 25 (75.8) 45 (71.4)
  Black 1 (3.3) 1 (3.0) 2 (3.2)
  Asian 4 (13.3) 3 (9.1) 7 (11.1)
  Unknown 1 (3.3) 4 (12.1) 5 (7.9)
  Other 4 (13.3) 0 4 (6.3)
Performance status, n (%)
  0 5 (16.7) 14 (42.4) 19 (30.2)
  1 23 (76.7) 18 (54.5) 41 (65.1)
  2 2 (6.7) 1 (3.0) 3 (4.8)
Patients with prior antineoplastic therapies, n (%) 30 (100.0) 33 (100.0) 63 (100.0)
Type of last therapy, n (%)
  Chemotherapy 16 (53.3) 18 (54.5) 34 (54.0)
  Targeted therapy 2 (6.7) 4 (12.1) 6 (9.5)
  Radiotherapy 10 (33.3) 5 (15.2) 15 (23.8)
  Surgery 0 4 (12.1) 4 (6.3)
  Other 0 5 (15.2) 5 (7.9)
  Missing 4 (13.3) 0 4 (6.3)
Best response at last therapy, n (%)
  Partial response 13 (43.3) 5 (15.2) 18 (28.6)
  Stable disease 5 (16.7) 16 (48.5) 21 (33.3)
  Progressive disease 9 (30.0) 9 (27.3) 18 (28.6)
  Unknown 2 (6.7) 2 (6.1) 4 (6.3)
  Not applicable 1 (3.3) 1 (3.0) 2 (3.2)
Predominant histology, n (%)
  Adenocarcinoma 0 29 (87.9) 29 (46.0)
  Squamous cell carcinoma 29 (96.7) 0 29 (46.0)
  Large cell carcinoma 0 3 (9.1) 3 (4.8)
  Large cell neuroendocrine carcinoma 0 1 (3.0) 1 (1.6)
  Othera 1 (3.3) 0 1 (1.6)
Stage at study entry, n (%)
  Stage IIIA 1 (3.3) 0 1 (1.6)
  Stage IIIB 1 (3.3) 2 (6.1) 3 (4.8)
  Stage IV 28 (93.3) 31 (93.9) 59 (93.7)
aOther histologies include large cell endocrine, adenoid, or squamous tumors.
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TABLE 2.  Summary of Tumor Molecular Alterations at Baseline for Enrolled Patients
Squamous
n = 30
Nonsquamous
n = 33
Total
N = 63
PIK3CA mutation status, n (%)
  n 29 31 60
  PIK3CA mutation 6 (20.7) 14 (45.2) 20 (33.3)
  PIK3CA wild-type 19 (65.5) 13 (41.9) 32 (53.3)
  Unknown 4 (13.8) 4 (12.9) 8 (13.3)
PTEN mutation status, n (%)
  n 29 30 59
  PTEN mutation 8 (27.6) 12 (40.0) 20 (33.9)
  PTEN wild-type 18 (62.1) 14 (46.7) 32 (54.2)
  Unknown 3 (10.3) 4 (13.3) 7 (11.9)
PTEN expression, n (%)
  n 29 25 54
  PTEN negative (<10% IHC) 18 (62.1) 6 (24.0) 24 (44.4)
  PTEN positive 11 (37.9) 16 (64.0) 27 (50.0)
  Unknown 0 3 (12.0) 3 (5.6)
PI3K pathway activation status, n (%)
  n 30 33 63
  PIK3CA mutation only 4 (13.3) 8 (24.2) 12 (19.0)
  PTEN mutation only 5 (16.7) 5 (15.2) 10 (15.9)
  PTEN negative only 12 (40.0) 2 (6.1) 14 (22.2)
  PIK3CA wild-type and PTEN alterationa 19 (63.3) 12 (36.4) 31 (49.2)
  PIK3CA mutation and PTEN alterationa 1 (3.3) 3 (9.1) 4 (6.3)
  PIK3CA mutation or PTEN alterationa 29 (96.7) 28 (84.8) 57 (90.5)
Patients with known PTEN mutation and expression status, n (%)
  n 25 18 43
  PTEN mutation and PTEN positive 6 (24.0) 6 (33.3) 12 (27.9)
  PTEN wild-type and PTEN negative 13 (52.0) 3 (16.7) 16 (37.2)
  PTEN mutation and PTEN negative 2 (8.0) 1 (5.6) 3 (7.0)
  PTEN wild-type and PTEN positive 4 (16.0) 8 (44.4) 12 (27.9)
Percentages were calculated from the number of samples assessed, n. “Unknown” includes patients whose tumors were assessed, but whose results were not evaluable. Concomitant 
mutations were calculated omitting samples with “unknown” or “missing” status as appropriate.
aPTEN alteration is defined as either PTEN mutation or PTEN negative.
IHC, immunohistochemistry; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog.
TABLE 3.  Best Overall Response per Investigator Assessment
Squamous
n = 30
Nonsquamous
n = 33
Best overall response, n (%)
  CR 0 0
  PR 1 (3.3) 1 (3.0)
  SD 12 (40.0) 12 (36.4)
  PD 7 (23.3) 9 (27.3)
  Not CR, not PD (NCRNPD) 1 (3.3) 2 (6.1)
  UNK 9 (30.0) 9 (27.3)
ORR (CR + PR), n (%) [95% CI] 1 (3.3) [0.1–17.2] 1 (3.0) [0.1–15.8]
DCR (CR + PR + SD + NCRNPD), n (%) [95% CI] 14 (46.7) [28.3–65.7] 15 (45.5) [28.1–63.6]
CI, confidence interval; DCR, disease control rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; UNK, unknown; ORR, overall 
response rate; NCRNPD, not complete response, not progressive disease.
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had PTEN-negative squamous NSCLC, and experienced 
a 31% reduction in size of target lesions. This patient had 
previously progressed on carboplatin–gemcitabine. Time to 
response was 41 days and duration of response was 73 days. 
The second patient with a PR had nonsquamous NSCLC 
harboring mutations in PIK3CA and KRAS, and experienced 
a 38% reduction in size of target lesions. This patient had 
progressed after a lung lobectomy followed by cisplatin–
pemetrexed chemotherapy. Time to response was 42 days 
and duration of response was 85 days.
Subsequent safety and efficacy data are reported for all 
63 patients enrolled in Stage 1, as of June 5, 2014. Median 
PFS was 2.79 months (95% CI: 1.38–3.71) in the squamous 
group, and 2.83 months (95% CI: 1.41–3.58) in the nonsqua-
mous group (Fig. 2A). Median OS was 7.98 months (95% CI: 
5.95–10.09) in the squamous group, and 7.20 months (95% 
CI: 4.01–9.92) in the nonsquamous group (Fig. 2B).
Safety and Tolerability
Median duration of exposure to buparlisib was 6.9 
weeks (range: 0.1–36.0) in the squamous group, and 6.7 
weeks (range: 1.4–79.6) in the nonsquamous group. Eight 
patients in each histology group remained on treatment for at 
least 12 weeks.
The most common AEs (≥25% of patients) regardless 
of relationship to study drug treatment were nausea, vomiting, 
and diarrhea (61.9%), asthenia/fatigue (49.2%), hyperglycemia 
(39.7%), liver toxicity (31.7%), and hypersensitivity/rash 
(28.6%; Table 4). A summary of AEs suspected to be related 
to study drug treatment experienced by patients in each histol-
ogy group is presented in Supplementary Table 2 (Supplemental 
Digital Content, http://links.lww.com/JTO/A850).
The most common Grade 3/4 AEs (≥5% of patients) 
suspected to be related to study drug treatment were hypergly-
cemia (23.3%), asthenia, and fatigue (6.7% each) in the squa-
mous group, and increased alanine aminotransferase (15.2%), 
increased aspartate aminotransferase, hyperglycemia (12.1% 
each), asthenia, and rash (6.1% each) in the nonsquamous group.
Of note, Grade 3 psychiatric AEs of anxiety, con-
fusional state, and visual hallucination (3.3% each) were 
observed in the squamous group, and depression and altered 
mood (3.0% each) in the nonsquamous group. No Grade 4 
psychiatric AEs were reported in either group. The most com-
mon AEs leading to discontinuation (≥5% of patients) were 
hyperglycemia (13.3%) in the squamous group, and dyspnea 
(9.1%), increased alanine aminotransferase, and depression 
(6.1% each) in the nonsquamous group. The most common 
serious AEs (≥5% of patients) were general physical health 
deterioration (13.3%), pneumonia (10.0%), dehydration, and 
hyperglycemia (6.7% each) in the squamous group, and dys-
pnea, hyperglycemia, and respiratory failure (9.1% each) in 
the nonsquamous group.
In total, there were nine on-treatment deaths. In the 
squamous group, four deaths were reported (three with study 
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FIGURE 1.  Waterfall plot of best percentage change in sum of diameters and best overall response, in (A) squamous and  
(B) nonsquamous groups. UNK indicates patients not qualifying for confirmed CR or PR and without SD after more than 5 weeks 
from the start of treatment. Patients assessed for best overall response but missing best percentage change from baseline 
are shown to the right; patients with unknown overall response and missing best percentage change from baseline are not 
included. One patient in the squamous group had a decrease in tumor measurement of greater than 30%, which was not 
confirmed at a subsequent assesment at least 4 weeks later, and was therefore classed as SD per RECIST v1.1. CR, complete 
response; NCRNPD, not complete response, not progressive disease; PD, progressive disease; PR, partial response; PTEN,  
phosphatase and tensin homolog; SD, stable disease; UNK, unknown.
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indication as the primary cause, and one due to sepsis, sus-
pected to be related to study treatment). In the nonsquamous 
group, there were five deaths (four due to study indication or 
disease progression, and one due to cardiogenic shock, not 
suspected to be related to study treatment).
Biomarker Analysis
Exploratory biomarker analyses were performed on 
the subset of tumor samples with sufficient material avail-
able. There was no evidence of a difference in median PFS 
between patients with PIK3CA mutation (20 patients) and 
PTEN alteration (41 patients; Supplementary Figure 2, 
Supplemental Digital Content, http://links.lww.com/JTO/
A850). Furthermore, when exploring the role of individual 
mutations within the PIK3CA gene, there was no evidence of 
a difference in median PFS between the 32 patients with wild-
type PIK3CA and the eight patients with “hot-spot” mutations 
(defined as E542K/V, E545K/A/G, and H1047R/L/Y/T,27 most 
likely to drive tumor growth and treatment resistance). Analysis 
of a panel of approximately 600 cancer-associated genes by 
NGS in 23 patients showed no evidence of association between 
PFS and the total tumor mutation burden (Supplementary 
Figure 3, Supplemental Digital Content, http://links.lww.com/
JTO/A850). The subset of patients with alterations in either 
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FIGURE 2.  Kaplan–Meier plots of 
(A) PFS and (B) OS in squamous and 
nonsquamous groups. Censoring 
times are shown as filled or open 
circles. CI, confidence interval; OS, 
overall survival; PFS, progression-free 
survival.
TABLE 4.  Adverse Events Observed in Patients per Specific 
Safety Event Category
Preferred Term, n (%)
Squamous
n = 30
Nonsquamous
n = 33
Total
N = 63
Nausea, vomiting, diarrhea 22 (73.3) 17 (51.5) 39 (61.9)
Asthenia/fatigue 14 (46.7) 17 (51.5) 31 (49.2)
Hyperglycemia 13 (43.3) 12 (36.4) 25 (39.7)
Liver toxicity 11 (36.7) 9 (27.3) 20 (31.7)
Hypersensitivity/rash 10 (33.3) 8 (24.2) 18 (28.6)
Mood disorders 3 (10.0) 5 (15.2) 8 (12.7)
Pneumonitis 3 (10.0) 0 3 (4.8)
QTc prolongation 1 (3.3) 0 1 (1.6)
Adverse events regardless of relationship to study drug treatment were described 
according to MedDRA v17.0, and are listed by specific safety event category in order of 
descending frequency in the “Total” column.
MedDRA, Medical Dictionary for Regulatory Activities.
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KRAS or EGFR appears to have a somewhat longer median 
PFS than wild-type patients, although the limited number of 
patients included in this analysis (three patients with KRAS 
mutation and five with EGFR mutation) should be noted.
PIK3CA mutations were also investigated in ctDNA. In 
38 patients for whom PIK3CA mutation status was confirmed in 
both tissue and ctDNA samples, the concordance for PIK3CA 
mutation was 55.3%.9 The concordance was 81.8% (9 of 11 
samples) between ctDNA and metastatic tissue, compared with 
44.4% (12 of 27 samples) between ctDNA and primary tissue.
DISCUSSION
BASALT-1 is the first study to assess an oral pan-Class I 
PI3K inhibitor in patients with squamous and nonsquamous 
metastatic NSCLC which exhibits PI3K pathway activation. 
Before screening and enrollment for BASALT-1, 1242 patients 
were prescreened for PI3K pathway activation between May 
2011 and September 2013—the largest such screen in squa-
mous and nonsquamous NSCLC to date.28 Among patients with 
known alteration status, PI3K pathway activation (defined as 
PIK3CA mutation, PTEN mutation, or PTEN expression nega-
tive) was exhibited in 15% and 11% of squamous and nonsqua-
mous NSCLC, respectively; alterations in PIK3CA and PTEN 
were broadly mutually exclusive in both histology types. The 
observed frequency of PI3K pathway alterations in squamous 
NSCLC was lower than that reported by a previous TCGA 
study, in which approximately 30% of 178 patients exhibited 
PIK3CA mutations or PTEN alterations.10 Meanwhile, our 
results in the nonsquamous group are in line with a previous 
TCGA study reporting that 10% of 230 patients with adeno-
carcinoma exhibited PIK3CA mutations or PTEN alterations.29 
The large, globally distributed population investigated in this 
study provides a good opportunity to estimate the actual fre-
quency of PIK3CA mutations and PTEN alterations in NSCLC; 
no differences were identified between ethnic groups.
All patients entered the study with advanced disease and 
had received prior antineoplastic treatment. At the cut-off date 
(June 5, 2014), all but one patient in the nonsquamous group 
had discontinued from treatment. The most common reasons 
for treatment discontinuation included AEs in the squamous 
group (36.7% of patients) and disease progression in the non-
squamous group (57.6% of patients). This difference may be 
explained by the higher associated comorbidity in patients 
with squamous NSCLC, as demonstrated by the higher aver-
age ECOG performance status. Of note, treatment exposure 
was short in both groups (6.9 and 6.7 weeks in squamous and 
nonsquamous NSCLC, respectively), and was curtailed due to 
rapid disease progression in almost half (47.6%) of the patients.
The safety and tolerability profile of buparlisib presented 
here is consistent with that observed in previous single-agent 
buparlisib trials—of particular interest, hyperglycemia and liver 
toxicities occurred in similar numbers of patients, and mood 
disorders were slightly less frequent than in previous trials.
Despite the rationale for BASALT-1—treating a 
selected patient population (NSCLC exhibiting PI3K path-
way activation) with a targeted agent (the pan-PI3K inhibitor 
buparlisib)9—the expected improvement in clinical outcome 
compared with chemotherapeutic agents in unselected patient 
populations was not observed: median PFS (2.79–2.83 months), 
median OS (7.20–7.98 months), and ORR (~3%) were similar 
to that observed with single-agent docetaxel.7 More recently, 
two targeted agents, afatinib and erlotinib, as second-line treat-
ments for squamous NSCLC have demonstrated a median PFS 
of 2.4 and 1.9 months, respectively.30 We therefore investigated 
whether the tissue samples used for determination of PI3K 
pathway activation were appropriate, and whether the detailed 
molecular profile revealed by NGS would identify potential 
biomarkers for lack of response to therapy.
Only two new biopsies were taken at study entry (one pri-
mary and one metastatic tumor), whereas 62 samples were from 
archival tissue (47 primary and 15 metastatic tumors). Hence, 
the majority of samples used for the determination of pathway 
activation were from archival primary tumors. An exploratory 
analysis of PIK3CA mutations in ctDNA in this limited sample 
set revealed a greater concordance with metastatic tissue than 
with primary tissue. Our results suggest either that metastases 
have acquired alterations not present in the primary tumor or 
that the biopsy tissue used for sequencing may not be repre-
sentative of the primary tumor. In both cases, the activation 
status in archival primary tissue samples may not match that 
at metastatic sites; hence sequencing of ctDNA may present 
an opportunity for more accurate characterization of tumor 
molecular status. However, even though ctDNA can be used to 
identify patients with PIK3CA mutations, the clinical outcome 
of this study does not support the use of PIK3CA mutation as a 
predictive marker for response to buparlisib therapy.
Further investigation of 23 patients with sufficient tumor 
tissue for NGS analysis did not identify any particular gene alter-
ation associated with a lack of response to PI3K inhibition (such 
as members of the mitogen-activated protein kinase pathway).31 
The observed frequencies of PIK3CA amplification and PTEN 
homozygous deletion detected were lower here than reported 
by a previous TCGA study,10 which could be due to the selec-
tion of patients with confirmed PIK3CA or PTEN alterations, 
or due to the different methodology used to detect copy num-
ber variations. KRAS alterations in this patient population were 
rare (only three patients with nonsquamous NSCLC harbored 
KRAS alterations), and in contrast to colorectal cancer, did not 
appear to be associated with a worse response to therapy.32 Of 
note, TP53 mutation, previously reported to activate the PI3K 
pathway, was the most common alteration detected by NGS, 
but showed no evidence of association with improved PFS. 
Overall, PI3K pathway activation has been observed in a clini-
cally relevant proportion of patients, and no alterations were 
identified in genes known to negatively regulate the PI3K path-
way. Therefore, the dependence on PI3K pathway activation of 
tumor growth and survival in NSCLC remains unclear.
In conclusion, despite preselecting patients with PI3K 
pathway-activated NSCLC, BASALT-1 did not meet its primary 
objective during Stage 1; the futility criterion was met in both 
squamous and nonsquamous groups. Although preclinical evi-
dence supported the rationale for PI3K inhibition in advanced 
NSCLC,9 alternative pathways may play an oncogenic role in 
this setting; however, given the involvement of PI3K pathway 
activation in treatment resistance,9 combining PI3K inhibitors 
with chemotherapy, immunotherapy, or other targeted agents 
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may improve efficacy compared to monotherapy, and warrants 
further investigation in future studies.
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